MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/1744666x.2022.2039630

Медицинская библиотека · Expert review of clinical immunology · 2022

Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.

Atzeni Fabiola, Popa Călin D, Nucera Valeria, Nurmohamed Michael T

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

To date, four Janus kinase inhibitors (JAKis) are licensed for the treatment of rheumatoid arthritis (RA) and/or psoriatic arthritis (PsA) in North America and/or Europe: tofacitinib, baricitinib, upadacitinib, and filgotinib. Most DMARDs have cardioprotective potential, yet for some of them, including JAKi, the modulatory effect on cardiovascular risk remains undetermined. Since their commercialization, the risk of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE) is taking on a relevant role in RA patients.

AREAS COVERED: In this article, we will review the effect of JAKi on CV risk and atherosclerosis process as major contributor to MACE. Furthermore, we will present the effect of JAKi on thromboembolic risk.

EXPERT OPINION: Although the effect of JAKi on CV and thrombosis is one of the most relevant topic regarding RA patients, it is necessary to underline that these patients have an increased risk of these comorbidities due to the inflammation process, and further study are needed in order to understand the real role of JAKi in controlling or inducing these complications.

Для цитирования: Atzeni Fabiola, Popa Călin D, Nucera Valeria, Nurmohamed Michael T. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.. Expert review of clinical immunology. 2022. DOI: 10.1080/1744666x.2022.2039630.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.